Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Next Previous
X
Search
Trial Profile

A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoblituzumab (Primary) ; Retifanlimab (Primary) ; Tebotelimab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MacroGenics

    • Most Recent Events

    • 08 Jul 2022 According to a MacroGenics media release, no additional patients in the study were to be enrolled or receive further treatments as of July 7, 2022.
    • 08 Jul 2022 According to a MacroGenics media release, The incidence of fatal events observed in the study that were potentially hemorrhagic in origin was higher than what has been reported for this patient population in the medical literature and in the context of a risk : benefit analysis.
    • 08 Jul 2022 According to a MacroGenics media release, this trial has been discontinued based on an internal review of safety data which is included the occurrence of seven fatalities potentially associated with hemorrhagic events in both arms. Six of the seven fatal events were secondary to disease progression and/or unrelated to the study treatment and one event was related.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top